- Home
- PRGS vs CRVS Comparison
PRGS vs CRVS Comparison
Compare PRGS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRGS | CRVS |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PRGS | CRVS |
|---|---|---|
| Price | $35.07 | $17.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $66.33 | $28.00 |
| AVG Volume (30 Days) | 1.1M | ★ 7.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.60 | N/A |
| Revenue Next Year | $1.28 | N/A |
| P/E Ratio | $21.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.81 | $2.54 |
| 52 Week High | $65.50 | $26.95 |
Technical Indicators
Market Signals| Indicator | PRGS | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 33.68 | 50.41 |
| Support Level | $35.26 | $18.50 |
| Resistance Level | $44.53 | $19.98 |
| Average True Range (ATR) | 2.03 | 1.50 |
| MACD | -0.63 | -0.79 |
| Stochastic Oscillator | 2.38 | 2.00 |
Price Performance
Historical ComparisonAbout PRGS Progress Software Corporation (DE)
Progress Software Corporation provides software operate in one operating segment: software products for the development, deployment, and management of responsible, AI-powered applications and digital experiences. Following are products: Chef, Corticon, Data Direct, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, WhatsUp Gold. Geographical regions include United States, Canada, EMEA, Latin America, and Asia Pacific.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).